Abbisko Cayman Limited (HK:2256) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbisko Therapeutics has revealed encouraging phase II trial results for their novel treatment combination of irpagratinib and atezolizumab in advanced hepatocellular carcinoma, demonstrating a 50% objective response rate in particular patient groups. The company aims to further investigate this treatment strategy, potentially offering a new hope for patients with this common and deadly form of liver cancer. While promising, the company cautions investors about the certainty of the drug reaching market success.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.